Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-02

Clinical Trial Update: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients [Phase 2]

View source ↗

Summary

Phase 2 biomarker study of secukinumab in rheumatoid arthritis has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-02